Status:
COMPLETED
Risk Factors for Thrombosis in Immune Thrombocytopenia
Lead Sponsor:
University Hospital, Toulouse
Conditions:
Immune Thrombocytopenia
Eligibility:
All Genders
18+ years
Brief Summary
Immune thrombocytopenia (ITP) is a rare autoimmune disease (annual incidence: 3-4/105 inhabitants) leading to an increased risk of spontaneous bleeding. ITP is said "primary" when not associated to ot...
Eligibility Criteria
Inclusion
- Incident primary ITP adults
Exclusion
- Secondary as well as prevalent ITP patients on July, 30th 2009 are excluded by the algorithm
Key Trial Info
Start Date :
February 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 31 2021
Estimated Enrollment :
10039 Patients enrolled
Trial Details
Trial ID
NCT03820960
Start Date
February 1 2019
End Date
March 31 2021
Last Update
September 5 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Toulouse
Toulouse, France